Daily Stock List
MedClean Technologies, Inc. (MCLN)
OTCPicks and OTC Advisors reported earlier on MedClean Technologies, Inc. (MCLN), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Bethlehem, Pennsylvania, MedClean Technologies, Inc. designs, sells, installs, and services on-site turnkey systems to treat regulated medical waste (RMW). They provide MedClean series systems as solutions to incineration, off site hauling of untreated waste, and other alternative treatment technologies and methodologies. MedClean markets their MedClean systems to medical waste generators, including hospitals, nursing homes, clinics, medical groups, health departments, laboratories, physicians, dentists, and veterinarians in private practice. The Company's shares trade on the OTC Bulletin Board.
MedClean Technologies solutions provide value in the form of cost savings, environmental safety and regulatory compliance. Their solutions provide risk mitigation. The MedClean® System is an advanced, turnkey sterilization and volume reduction solution for RMW, including "sharps". It is available in container and mobile configurations, along with fixed configurations for installation within a healthcare facility.
Their MedClean system includes an assortment of equipment, machinery, and services, such as an autoclave vessel to sterilize the medical waste. The system also includes the MedClean Shredder to convert sterilized waste material into non-recognizable confetti-like material qualifying the end product as safe municipal solid waste. In addition, the system includes the AutoTouch control station with software and hardware components that integrate and bundle operating and data recording functions into a system for the conversion and disposal of medical waste.
The MedClean system consists of a material transporter to transport mechanically the processed waste from shredder to the municipal solid waste compacting dumpster. Moreover, their system consists of a QuietCart transport cart system to facilitate a single source containerization of the infectious waste from generation, sterilization, processing, and return for refill, and services to transport the waste from the point of generation through the point of treatment. Concerning Equipment & Technology, MedClean provides Autoclave and Shredder based equipment. These consist of fixed custom built, self-contained units, and portable or mobile solutions.
The Company provides Technology enabled Services (TeS). This combines medical waste treatment technology and supporting services. MedClean Technologies can offer transportation on diverse waste streams, equipment, or Technology enabled Services (TeS), or a combination of both.
MedClean Technologies, Inc. (MCLN), closed today at $0.0001, even for the day, on 3,523,000 volume with 7 trades. The average volume for the last 60 days is 3,911,630 and the stock's 52-week low/high is $0.0001/$0.0009.
NSU Resources, Inc. (NOST)
OtcWizard reported recently on NSU Resources, Inc. (NOST), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.
Based in Sault Ste Marie, Ontario, NSU Resources, Inc. engages in the exploration and development of rare earth metal properties. The Company is pursuing the development of proven NI 43-101 compliant ore inventories from high quality properties with the potential for providing topside ore of good quality. The Company was formerly known as Bio-Carbon Solutions International, Inc. They changed their name to NSU Resources, Inc. in December 2011. NSU Resources lists on the OTC Markets' OTCQB.
NSU Resources will be pursuing Canadian- and world based properties. Currently, the Company is focusing on their Eastern Canada property. Their Byers Brook Property is in Colchester County, Nova Scotia. It consists of Mineral Exploration License 09388, which contains 27 claim units (1080 acres or 437 hectares). The Property is within a geological environment favorable for the discovery of Iron-Oxide-Copper-Gold (IOCG). Other types of mineralization include Rare Earth Element (REE) mineralization (MacHattie, 2010) and Volcanogenic Massive Sulphide (VMS).
The Company's Shatter Lake Property is in Colchester County, Nova Scotia. It consists of Mineral Exploration License 08996, which contains 78 claim units (3120 acres or 1263 hectares). The Property is within a geological environment that is favorable for the discovery of Rare Earth Element (REE) mineralization similar to nearby recent discoveries (MacHattie, 2010). Other types of mineralization such as Volcanogenic Massive Sulphide (VMS) and Iron-Oxide-Copper-Gold (IOCG) have also been reported within the Cobequid Highlands Area.
In July 2012, NSU Resources reported that they fully exercised their mineral rights options from the Byers Brook and Shatter Lake claims in Nova Scotia. The region is the object of renewed mineral exploration efforts owing to the recent findings of Rare Earth Elements (2010) and Gold (2011).
Concerning Technology, NSU Resources has created a proprietary methodology for the extraction of rare earths based on the anticipation profile of rare earths from the Company's Nova Scotia properties. This process will be the object of international protection through the Patent Cooperation Treaty (PCT). It will provide NSU protection for 36 months in the 103 countries that are members of the PCT. Subsequently, they will enter into the national phase of patent protection in Canada, the U.S., the EU and other countries as they see the need to protect their interest. The Company believes that this intellectual property (IP) offers significant business advantages to NSU Resources.
NSU Resources, Inc. (NOST), closed at $0.035, up 75.00%, on 26,666 volume with 3 trades. The average volume for the last 60 days is 362,809 and the stock's 52-week low/high is $0.0014/$0.23.
Brixton Metals Corp. (BBB.V)
Vantage Wire reported previously on Brixton Metals Corp. (BBB.V) and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Brixton Metals Corp. is an exploration company with corporate headquarters in Vancouver, British Columbia. The Company engages in the exploration of precious metal assets and advancing them to feasibility. Brixton is focusing on the exploration of gold, silver, and base metal deposits at unrecognized geological targets. Their flagship property is the Thorn Project in northwestern British Columbia (BC). Brixton Metals' shares trade on the TSX Venture Exchange.
The Thorn property is centered on high-grade silver-gold-lead-zinc-bearing breccia-diatreme zones, high-grade Ag-Au-Cu veins and potential porphyry targets. The Thorn Property is located between the past producing Golden Bear Mine and Chieftain's Tulsequah Chief Mine Development. The property is approximately 130 km south from the village of Atlin, BC. The earliest known work on the Thorn property was carried out by Kennco Explorations (Western) Ltd. in 1959 during a regional exploration program.
Brixton Metals entered into a non-binding letter agreement dated January 7, 2013 to acquire a 100 percent interest in the Thorn Property from Rimfire Minerals a subsidiary of Kiska Metals. Brixton has agreed to pay to Kiska $1.5 million in cash and issue 7,000,000 shares in their capital stock to acquire the Thorn Property by February 28, 2013.
The Thorn Property is 25,000 hectares. It has the potential to host a high unit value polymetallic mineral deposit. The Company's exploration of Thorn is concentrating on a network of high sulphidation epithermal veins and breccia zones. A two phase, 26 hole drill program consisting of 2,889m was completed in 2012 at Thorn. This drilling was directed almost entirely at the Oban breccia zone, to follow up on the bonanza grade silver discovery made in 2011, reported in January 2012.
The 2012 drill program produced a number of results including Hole THN12-84, which intercepted 123.00m of 402.52 g/t AgEq (190.68 g/t Ag, 1.19 g/t Au, 3.25 percent Zn, 1.74 percent Pb and 0.06 percent Cu) within broader intervals of 201.00m of 303.64 g/t AgEq and 310.00m of 223.52 g/t AgEq.
The 2013 program at Thorn is planned to include expansion drilling at the Oban zone, drill testing to the south, north and at depth: drill testing the Oban-sister IP anomaly to the east. It will also include infill and expanding the 3d IP geophysical survey centered around the Oban area; infill and expanding soil sampling over the anomalies identified in 2012 in the Amarillo area, and infill and expanding soil sampling over the large Outlaw geochem anomaly.
Brixton Metals Corp. (BBB.V), closed today's session at $0.145, up 3.57%, on 167,850 volume. The stock's 52-week low/high is $0.08/$0.26.
Inrad Optics, Inc. (INRD)
We are reporting on Inrad Optics, Inc. (INRD) today, here at the QualityStocks Daily Newsletter.
Inrad Optics, Inc. develops, manufactures and markets products and services for use in photonics industry sectors through three distinct but complimentary product areas: "Crystals and Devices", "Custom Optics" and "Metal Optics." Incorporated in New Jersey in 1973, the Company formerly went by the name Photonic Products Group, Inc. In January 2012, the Company's Board of Directors and shareholders approved the name change to Inrad Optics, Inc. Listed on the OTC Bulletin Board; the Company has their corporate headquarters in Northvale, New Jersey. They also have a facility in Sarasota, Florida.
Inrad Optics' components and value-added photonic devices are used in a broad array of defense, aerospace, laser, medical, process control and metrology applications. The Company's customers include leading corporations in the defense, aerospace, laser systems, process control and metrology sectors of the photonics industry, as well as the U.S. Government, National Laboratories and Universities around the world.
The Company specializes in applying advanced manufacturing systems to crystal, glass and metal substrates. Their manufacturing expertise includes solution and high-temperature crystal growth, precision diamond turning, and thin-film and other optical coatings. Additionally, it includes large substrate production, in-process metrology expertise, as well as optical systems assembly.
Their design expertise includes design for manufacturability, electro-optic integration, and opto-mechanical design. Inrad Optics' products include crystal components, crystal devices and systems, UV filter crystals, X-Ray crystals, custom optics (such as beam splitters, prisms, and polarizers), and metal optics (such as scan mirrors and parabolas and off-axis parabolas).
Last month, Inrad Optics announced the recent promotion of Mr. George Murray to Vice President of Sales and Marketing. Mr. Murray joined Inrad Optics as Sales Manager, West Region in 2010. Before joining Inrad Optics, he held increasingly responsible roles in applications engineering, product marketing, and sales management including international sales. Mr. Murray holds a Bachelors of Science degree in Mechanical Engineering from the University of Connecticut and an MBA from Rensselaer Polytechnic Institute, Hartford Campus.
Inrad Optics, Inc. (INRD), closed Tuesday's trading session at $0.35, up 25.00%, on 2,500 volume with 1 trade. The average volume for the last 60 days is 101,647 and the stock's 52-week low/high is $0.185/$1.00.
American Graphite Technologies, Inc. (AGIN)
Today we are highlighting American Graphite Technologies, Inc. (AGIN), at the QualityStocks Daily Newsletter.
Founded in 2010, American Graphite Technologies, Inc. is a mineral exploration and technology development company. They are focusing on securing graphite mining opportunities and the commercialization of graphene specific proprietary technology methods. The Company formerly went by the name Green & Quality Home Life, Inc. They changed their name to American Graphite Technologies, Inc. in July 2012. The Company lists on the OTC Bulletin Board and has their headquarters in Las Vegas, Nevada.
Graphene is believed to be stronger than steel and more conductive than copper, while being flexible. This makes it feasible as a replacement over silicon possibly leading to thinner, faster, cheaper, more flexible devices including power sources. Graphene comes from the carbon atom; therefore, it is abundant and cheap.
Concerning their mining assets, American Graphite Technologies has their Lac Nicolas Graphite Property. They have 100 percent ownership of 100 mineral claims covering approximately 5,400 hectares (13,343 acres) of land in the Province of Quebec. No Royalty or Net Smelter Return (NSR) is attached to this property. The property is in an underexplored relatively new graphite exploration area with significant upside potential for new discoveries. The earliest exploration work in the area was carried out in the late 1950's to the early 1960's.
Geologically, the Lac Nicolas Graphite Property is underlain by rocks of Granville Province and Archean basement and is similar to other graphite deposit/discoveries in the area. The Property is part of the area designated as "Plan Nord" for major economic, social and environmental development as announced by the Quebec Government.
In January, American Graphite Technologies announced that they entered into and executed a non-exclusive technology License agreement for patent and trade secret technology in the field of graphene oxide "bucky" paper with Cheap Tubes, Inc. With this agreement, American Graphite will fund the further development and commercialization of certain proprietary inventions and expertise related to the manufacturing process for graphene products, including graphene paper and Bucky Paper. They agreed to fund commercial development and received a license for the rights on a non-exclusive basis for marketing products and/or services.
American Graphite Technologies, Inc. (AGIN), closed Tuesday's trading session at $0.55, up 14.58%, on 13,000 volume with 3 trades. The average volume for the last 60 days is 2,603 and the stock's 52-week low/high is $0.40/$0.85.
Canyon Copper Corp. (CNYC)
Bull Ventures and Stock Guru reported earlier on Canyon Copper Corp. (CNYC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Incorporated on January 21, 2000, Canyon Copper Corp. is an exploration stage company whose shares trade on the OTC Bulletin Board. They engage in the acquisition, exploration and development of mineral properties. The Company formerly went by the name Aberdene Mines Limited and they changed their name to Canyon Copper Corp. in August of 2006. Canyon Copper has their headquarters in Vancouver, British Columbia.
Currently, the Company holds 100 percent title in a major claim block totaling 661 unpatented mineral claims, covering approximately 13,220 acres located in Mineral County, Nevada (the New York Canyon Claims). In addition, they hold 21 patented mineral claims covering an area of approximately 420 acres, located within the vicinity of the New York Canyon Claims area. Canyon Copper collectively refers to the New York Canyon Claims and the patented claims as the "New York Canyon Project."
Furthermore, Canyon Copper holds an option to acquire a 100 percent interest in the "Moonlight Property". This Property is subject to a 70 percent earn-in by Sandfield Resources Ltd. The Moonlight Property is a copper porphyry project consisting of 307 unpatented mineral claims having an area of approximately 6,300 acres located on the northern end of the Walker Lane Belt in Plumas County, California.
Over the next twelve months, the Company's plan of operation is to complete exploration programs on their mineral properties. Phase One of their exploration program on the New York Canyon Project involves the re-analysis of the 2006 Longshot Ridge drill pulps and initiating environmental base line studies, which will permit Canyon Copper to conduct advanced exploration, if warranted. Subject to obtaining financing, they plan to drill test the oxide mineralization found to the north and northeast of the Longshot Ridge deposit. This represents the initial stages of Phase Two of their exploration program on the Project.
Concerning the Moonlight Property, during the term of the Earn-In Agreement, the Company is not planning to conduct any exploration activities on the Property. Last month, Canyon Copper announced that they entered into an agreement with Sandfield Resources Ltd. Canyon has agreed to transfer to Sandfield up to a 70 percent interest in their optioned Moonlight Copper-Porphyry Property.
Canyon Copper Corp. (CNYC), closed Tuesday's trading session at $0.059, down 14.62%, on 191,750 volume with 14 trades. The average volume for the last 60 days is 41,869 and the stock's 52-week low/high is $0.04/$0.155.
YaFarm Technologies, Inc. (YFRM)
We are highlighting YaFarm Technologies, Inc. (YFRM) today, here at the QualityStocks Daily Newsletter.
YaFarm Technologies, Inc. previously offered a range of business-class Website development and Web hosting products and services to small and medium-sized businesses in the United States. Today, the Company announced that they signed a definitive agreement with the Integrative Stem Cell Institute. YaFarm Technologies was founded in 2003. The Company has their corporate headquarters in Pittston, Maine. Their shares trade on the OTC Markets' OTC Pink Current Information.
As of December 14, 2012, Mr. Brian Hermenze was appointed as YaFarm Technologies President and a Director. Mr. Hermenze, for the past five years, has been a private investor, specializing in small-cap growth companies. Mr. Hermenze previously held the NASD Series 7, 24, and 63 licenses and worked as a Financial Advisor with a number of investment banking firms in the New York City area.
As of December 14, 2012, Mr. Cody McDowell was appointed as the Company's President and a Director. Mr. McDowell, currently a private investor, is a recent Graduate of Colorado State University, where he obtained a degree in Exercise Science obtaining a thorough knowledge in the exercise development field and rehabilitation of the human body.
Today, YaFarm Technologies announced that they signed a definitive agreement to acquire the aforementioned Integrative Stem Cell Institute (the ISCI). The ISCI is a pioneer in the field of cell-based regenerative medicine. They combine a world-class medical facility with a state-of-the-art laboratory.
The ISCI provides investigational treatments to patients as part of clinical studies. This is while providing long-term follow up to advance these promising therapies. The acquisition of the ISCI provides YaFarm Technologies with an entry into stem cell research and treatment.
YaFarm Technologies President, Mr. Brian Hermenze, stated, "Since the 2012 Nobel Prize in Physiology or Medicine was awarded jointly to John B. Gurdon and Shinya Yamanaka for their work in stem cell research, we are very excited about the synergies this acquisition will bring to the Company. The ISCI has been providing point-of-care therapies to patients for over a year and operates at an internationally recognized medical facility accredited by both the Joint Commission and Accreditation Canada International."
Moreover, today the Company also announced that they received final approval from the Financial Industry Regulatory Authority (FINRA) for a 4 for 1 forward stock split. To receive the dividend the investor must be a registered shareholder of record on the Company's books on or before the record date of January 18, 2013. Shares of YaFarm Technologies began trading ex-dividend on January 22, 2013.
YaFarm Technologies, Inc. (YFRM), closed Tuesday's session at $0.1586, up 164.33%, on 12,320,821 volume with 938 trades. The average volume for the last 60 days is 19,167 and the stock's 52-week low/high is $0.0125/$0.0125.
Kilo Goldmines Ltd. (KGL.V)
Stockhouse reported previously on Kilo Goldmines Ltd. (KGL.V), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Kilo Goldmines Ltd. is gold exploration company that lists on the TSX Venture Exchange. The Company holds exploitation and exploration licenses covering approximately 3000 km2 of favorable Archaean Kabalian greenstone in the Kilo-Moto area in the Democratic Republic of the Congo (DRC). Incorporated in Ontario, Canada in January 2006, Kilo Goldmines has gold and iron ore prospects and resources in the northeastern portion of the DRC and a non-participatory, subject to dilution interest (20 percent), in an iron ore prospect in Afghanistan - the "Hajigak Project". Kilo Goldmines is based in Toronto, Ontario.
The Company owns a 71.25 percent interest in KGL-Somituri SPRL (the Somituri Project) - the registered holder of mineral rights on eight non-contiguous Exploitation Licenses valid until 2039 covering 606 km2 which includes the Imbo license (122 km2). Kilo has defined a 1.87 Moz, NI 43-101 compliant inferred gold resource estimate (1.63 g/t Au, at a cut-off grade of 0.5 g/t) on the Adumbi Prospect (April 2012) of the Imbo license.
Kilo Goldmines' strategy is to advance, solely or in partnership, their gold and iron ore prospects and resources. Their short and long-term business plans include delineating and developing a multi-pit resource of a sufficient grade and size on the Imbo License (Somituri Project), which will support a mine of regional significance. Their plans also include defining drill targets, discovering in-situ gold mineralization and ultimately, delineating gold resources and developing one or more mines on the other seven exploitation Licenses forming part of the greater Somituri Project.
The Company's plans also include advancing their iron ore collaboration with Rio Tinto Plc for the development and realization of KWR Iron SPRL's iron ore assets. Furthermore, their plans include strategic partnerships with established players who have the capacity to develop world class gold mines in the northeast DRC, and leveraging their shareholding in the Hajigak iron ore project.
In January, Kilo Goldmines announced results from diamond drill hole SKDD0035 (#35) totaling 293.20 m, an undercut hole of the previously announced drill hole SKDD0021 (#21), that intersected 5.80 m @ 42.24 g/t Au. The Kitenge Prospect is now defined over a 1500 m strike length and is one of several exploration Prospects that form part of Kilo Goldmines' Somituri Project in northeastern DRC. Kitenge is approximately 4.0 km from the Company's 1.87 Moz Adumbi inferred gold resource estimate and like Adumbi, falls within the Imbo License. Kilo intersected additional high grade targets at Kitenge: 3.75 M grading 27.08 g/t Gold.
Kilo Goldmines Ltd. (KGL.V), closed Tuesday's trading at $0.10, down 4.76%, on 35,355 volume. The stock's 52-week low/high is $0.08/$0.26.
Consorteum Holdings, Inc. (CSRH)
The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0093, up 86.00%, on 439,030 volume with 6 trades. The stock’s average daily volume over the past 60 days is 114,019, and its 52-week low/high is $0.001/$0.02.
Consorteum Holdings, Inc. (CSRH) utilizes the most technically advanced global solutions available today. By working with a multitude of global technologies, Consorteum is able to create customized programs for maximum results. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.
Through its exclusive software license with Tarsin Inc., the company leverages a team of software developers that understands the complexities of delivering digital media content across mobile handsets. Tarsin is capable of providing clients with integration and support for over 700 mobile carriers globally on a seamless and secure platform to take advantage of the increasing demand for rich mobile content.
Consorteum's flagship CAPSA technology platform brings a universal solution to the problems of wagering and betting on mobile devices. Multiple different operating systems, user interfaces, and form factors have created enormous barriers to launching commercial initiatives. But with CAPSA, gaming operators can now cost-effectively monetize innovative mobile wagering products and services quickly and robustly.
In addition to its mobile initiatives, Consorteum is also actively engaged in the financial industry, providing MasterCard solutions as well as loyalty and reward programs. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer
Consorteum Holdings, Inc. Company Blog
Consorteum Holdings, Inc. News:
Consorteum Holdings Files Form 10-K Report With the Securities and Exchange Commission
CORRECTION -- Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Tarsin, a Leader in Secure Mobile Platform Technology, Forges New Frontiers in Mobile Gaming
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.096, up 24.51%, on 8,681,956 volume with 470 trades. The stock’s average daily volume over the past 60 days is 3,513,520, and its 52-week low/high is $0.0275/$0.16.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis to Present at the 6th Annual OneMedForum
Advaxis Appoints Daniel J. O'Connor to Senior Vice President, Chief Legal and Business Development Officer
Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.39, up 9.24%, on 567,648 volume with 131 trades. The stock’s average daily volume over the past 60 days is 200,885, and its 52-week low/high is $0.161/$0.65.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson's Disease
International Stem Cell Corporation Announces Positive Animal Efficacy Results in Liver Disease Program
International Stem Cell Corporation to Participate in Biotech Showcase 2013 on January 7th
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.80, up 0.63%, on 4,565 volume with 5 trades. The stock’s average daily volume over the past 60 days is 1,808, and its 52-week low/high is $0.06/$3.10.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium
Advaxis, a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases, is developing a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to the bacteria to the cancer itself.
The company’s approach has been determined to outsmart tumor protection reactions that foil other treatments, while also generating a long-term immune system “memory” that is able to hunt down cancer cells throughout the body beyond the initially targeted antigens. And, being an immunotherapy, it does it all without the poisons and associated side effects of traditional chemotherapy treatments.
Advaxis immunotherapies are designed to stimulate many complementary immune mechanisms of action, including:
• Strong innate immune effects
• Strong adaptive immune effects
• Reduction of both Tregs and MDSCs in tumors but not in other tissues or systemically
• Memory generation that is not impaired by antibiotics administered immediately after dosing
• Chemotaxis and extravasation of activated immune cells
• Upregulation of tumor chemokines and chemokines receptors
• Epitope and antigen spreading
• A predominantly cellular immune response with little antibody formation
Over 15 distinct constructs are in various stages of development, either developed directly by Advaxis or through strategic collaborations with recognized centers of excellence, such as the National Cancer Institute. The company’s first construct, ADXS-HPV, is being evaluated in 4 Phase 2 clinical trials for HPV associated diseases (CIN 2/3, cervical cancer, and head & neck cancer). In addition, Advaxis has developed immunotherapies for prostate cancer and HER2 expressing cancers (such as breast, gastric, bladder, brain, pancreatic, ovarian cancer, and canine osteosarcoma).
For additional information, visit www.Advaxis.com
Cardium Therapeutics has a capital-efficient, asset-based business strategy focused on building a diversified portfolio of new and innovative bio-medical product opportunities and businesses, leveraging research and development investments by big pharma, venture, and institutional investors. A key component to that strategy is the company’s Excellagen advanced wound care management platform, which has already received FDA 510(k) clearance for U.S. marketing and sales.
Excellagen is a syringe-based flowable topical gel that promotes the activation of the healing process for the treatment of dermal wounds. It is designed to accelerate granulation tissue growth in non-healing wounds and activates platelets, triggering the localized release of endogenous growth factors including Platelet-Derived Growth Factor (PDGF), a key biologic mediator of wound healing.
Its initial focus is for diabetic foot ulcers, a significant problem in the U.S. with its growing population of diabetic patients. The Excellagen plan is consistent with the company’s strategy of supporting initial market introduction, seeding the market, and then monetizing through strategic partnerships and distribution deals, both domestically and internationally.
Principal commercialization factors:
• Excellagen is the best-in-class acellular biological modulator designed to accelerate the growth of granulation tissue for wound healing.
• Excellagen has FDA clearance for the treatment of a broad array of dermal wounds.
• Excellagen is competitively positioned, offering an aseptically manufactured, pharmaceutically-formulated collagen in a flowable syringe-based format that is easy to use.
• Excellagen has multiple clinical studies backing up its unique effectiveness.
• Selected as 2012 Top 10 Innovation in Podiatry by Podiatry Today magazine.
• Excellagen outsourced supply chain is fully operational, including U.S. cold chain distributor: Smith Medical Partners.
International CE mark registration for Excellagen is targeted for 1Q/2013
For additional information, visit www.CardiumTHX.com
Capstone Turbine, the preeminent clean technology manufacturer of microturbine energy systems worldwide, announced today that it has received a follow-on order of 5 MW from a global upstream oil and gas producer. The order consists of five C1000 power packages that will be installed in the Eagle Ford Shale play in Texas. Upon completion of the installation, Capstone will have 10 MW of energy systems in the Eagle Ford play.
Capstone distributor Horizon Power Systems secured both the initial order and this latest follow-on order for five megawatts.
“North American shale gas producers are continuing to adopt Capstone microturbines because they want the high reliability and low emission benefits of our products,” said Sam Henry, Horizon Power Systems President. “In addition, this customer is committed to conducting business safely, in a socially and environmentally responsible manner which is precisely what Capstone microturbines deliver.”
The Eagle Ford Shale is consistently producing hydrocarbons from its vast array of oil and natural gas fields. The shale play occupies an area starting at the Texas-Mexico border in Webb and Maverick counties and reaching 400 miles toward East Texas. It is 50 miles wide and an average of 250 feet thick at a depth between 4,000 and 12,000 feet. The hydraulic fracturing process used to produce oil or gas will be easier than usual to implement with this particular shale because it contains a high amount of carbonate. As a whole, the oil reserves contain an estimated 3 billion barrels with a potential output of 420,000 barrels a day.
Capstone’s microturbine technology will be used to power liquid processing plants and will be placed at several central gathering plants. Pipeline quality gas is used to fuel the microturbines in order to provide the electricity to power all onsite equipment, including heaters, pump motors, compressors, and distribution panels.
Capstone continues its penetration of the North American shale gas market with another substantial order from an existing customer. “The oil and gas market continues to be our fastest growing market worldwide,” said Jim Crouse, Capstone’s Executive Vice President of Sales and Marketing.
“Most of today’s global oil and gas companies operate in unique geographical, environmental and socially challenging areas in relatively isolated parts of the world. It is important that when they operate in these sensitive ecological areas near local communities they select the right state of the art equipment,” said Darren Jamison, Capstone’s President and Chief Executive Officer.
For further information, please visit www.capstoneturbine.com
Citadel Exploration, an operator with some 52k acres at their Rancho Grande project in the San Joaquin Basin and another 688 acres at Project Indian in the Salinas Basin, reported raising $1.39M today via a 4.086M share private placement at $0.34 per common share (no commissions paid).
This is a huge move for the company as it will allow for serious exploration and development at the company’s two primary sites in the heart of the oil-hungry California market, which currently is only able to field roughly 37% of its refined oil via in-state production. Rancho Grande in particular holds abundant recovery potential and Citadel, alongside operating partner Sojitz
Energy Ventures, is in a prime position to exploit that potential, having identified 23 prospects on the site already with multiple hydrocarbon zone targets.
President and CEO of COIL, Armen Nahabedian, whose family has been active in oil exploration in the San Joaquin Basin region for generations now, called the raising of this capital a real testament to the abilities of recently hired CFO, Phil McPherson. Nahabedian said this deal really cements McPherson’s position with the company and projected huge return value for shareholders should the planned, upcoming drilling programs be successful.
Not much reason to expect they wouldn’t be after even a cursory analysis of the acreage currently within striking distance, as the primary site, Rancho Grande, affords a host of targets in conventional oil zones from 1.5k all the way down to 22k feet (immediate shallow and longer-term horizontal potential). The company plans to start drilling at Rancho Grande as soon as March, and the well by well engagement basis for COIL (various working interests depending on prospect) leaves the company in a very de-risked/spry position with tremendous upside. Projections for recovery are quite nice as well, with around 50 to 200k BOE per prospect and 100 to 200 BOPD, with operators like Occidental Petroleum on adjoining leases showing superb results from both conventional and horizontal drilling activities.
Also, given the advanced state of logistics in the area, it should be really easy for the company to bring new infrastructure online quickly and get product out to the LA refinery market, just a 60 mile drive away. Permits are already obtained for portions of Rancho and the company is currently making determinations about the well program, with every intention at COIL being to update markets as soon as the specifics are hammered out.
The Project Indian leasehold over in the Salinas Basin is actually on land owned by Occidental Petroleum subsidiary, Vintage Petroleum. Citadel, again acting as operator, is currently looking at a 5-well pilot program here and is in a 60/40 WI position alongside JV partner Sojitz. Permitting is in its final stages with a Q2 kick off this year slated for the start of the pilot program.
The project is noteworthy because roughly half of CA’s oil production comes out of shallower heavy oil via thermal recovery methods, and the pilot program is designed from the ground up to test the overall economic viability of this approach (11 to 17 API oil via prior drilling). Given the upwards of $10.00/barrel premium over WTI prices currently fetched by heavy oil’s like Midway Sunset (as per Chevron’s data) and the rapidly expanding natural gas markets associated with historically record-low gas prices, heavy oil is extremely compelling from a profitability and longer-term development standpoint. The natural gas technology already cropping up around the idea of all this abundant domestic production is enough to make the dynamics compelling on its own, even before considering the 100M barrels plus of original oil in place estimated at Indian.
Veteran management with an even generational knowledge base in the regional geology, as well as a deep understanding of the history of techniques for E&P in the region, is something that gives COIL a real edge on the competition here and markets will be eager to look for more news in coming weeks as the finer points of the company’s drilling programs emerge.
For more information on Citadel Exploration, visit www.CitadelExploration.com
Today's Top 3
The QualityStocks Public Company Sponsor News